SCHEMBL15467441

SCHEMBL15467441

OC1(c2ccc(Cl)cc2)CCOc2cccnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 4/20 0.49
SCN9A Q15858 2/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
CREBBP Q92793 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
POLB P06746 1/20 0.33
SLC6A3 Q01959 2/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
AVPR1A P37288 1/20 0.32
P2RX7 Q99572 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467925 0.87 MAP3K14 (0.41) MAP3K14ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL15467914 0.87 MAP3K14 (0.49) MAP3K14ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL15468024 0.86 MAP3K14 (0.38) MAP3K14TRPM8SLC6A3SLC6A2P2RX7
SCHEMBL15467268 0.85 MAP3K14 (0.41) MAP3K14SMN1; SMN2TRPM8SLC6A3SLC6A2
SCHEMBL15467986 0.83 TRPM8 (0.37) MAP3K14SCN9ATRPM8P2RX7
SCHEMBL15467483 0.82 MAP3K14 (0.39) MAP3K14TRPM8SLC6A3SLC6A2SLC6A4
SCHEMBL15467465 0.80 TRPM8 (0.51) MAP3K14SCN9ATRPM8SLC6A3SLC6A2
SCHEMBL15469368 0.78 MAP3K14 (0.44) MAP3K14ALDH1A1GAAMAPTTRPM8
SCHEMBL15467083 0.77 TRPM8 (0.40) TRPM8P2RX7
SCHEMBL15467331 0.75 PDE2A (0.38) MAP3K14TRPM8P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAP3K14 1097/4885SCN9A 66/4885ALDH1A1 4469/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAP3K14 1097/4885SCN9A 66/4885ALDH1A1 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.